Letters
We still need artesunate monotherapy
BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7557.45 (Published 29 June 2006) Cite this as: BMJ 2006;333:45
- François Nosten (SMRU@tropmedres.ac), director,
- Elizabeth Ashley,
- Rose McGready,
- Ric Price
- Shoklo Malaria Research Unit (SMRU), Mae Sot, 63110 Thailand
- Shoklo Malaria Research Unit (SMRU), Mae Sot, 63110 Thailand
EDITOR—Seen from Geneva, the World Health Organization's “ultimatum” on artemisinin monotherapy may seem a landmark in prolonging the useful therapeutic life of the artemisinin derivatives,1 but for the clinicians in the field, the matter is different.
In 1991 on the Thai-Myanmar border we were facing the prospect of untreatable Plasmodium falciparum malaria as drug resistance emerged to standard antimalarial agents. The problem was circumvented by combining artesunate or …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.